HC Wainwright Raises Krystal Biotech (NASDAQ:KRYS) Price Target to $56.00

Share on StockTwits

Krystal Biotech (NASDAQ:KRYS) had its price target increased by HC Wainwright from $38.00 to $56.00 in a report released on Monday, Briefing.com Automated Import reports. They currently have a buy rating on the stock.

KRYS has been the topic of a number of other reports. Guggenheim started coverage on shares of Krystal Biotech in a research note on Thursday, May 30th. They set a buy rating and a $31.57 price target on the stock. William Blair reaffirmed a buy rating on shares of Krystal Biotech in a research note on Monday. Zacks Investment Research cut shares of Krystal Biotech from a hold rating to a sell rating in a research note on Friday, March 22nd. Cowen reaffirmed a buy rating on shares of Krystal Biotech in a research note on Monday, May 6th. Finally, BidaskClub cut shares of Krystal Biotech from a buy rating to a hold rating in a research note on Tuesday, June 18th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $49.83.

Shares of KRYS opened at $39.40 on Monday. The company has a quick ratio of 33.28, a current ratio of 33.28 and a debt-to-equity ratio of 0.03. The firm has a market cap of $595.08 million, a PE ratio of -40.62 and a beta of 0.73. The firm has a fifty day moving average price of $32.21. Krystal Biotech has a 1 year low of $13.75 and a 1 year high of $46.90.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. On average, sell-side analysts anticipate that Krystal Biotech will post -1.42 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the company. Knott David M acquired a new position in shares of Krystal Biotech during the 4th quarter worth $31,000. New York State Common Retirement Fund acquired a new stake in Krystal Biotech in the 4th quarter valued at about $159,000. TD Asset Management Inc. acquired a new stake in Krystal Biotech in the 1st quarter valued at about $268,000. MYDA Advisors LLC acquired a new stake in Krystal Biotech in the 1st quarter valued at about $296,000. Finally, Citigroup Inc. acquired a new stake in Krystal Biotech in the 4th quarter valued at about $214,000. 46.05% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.

See Also: How to interpret a stock’s beta number

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Royal Bank of Canada Trims Russel Metals  Target Price to C$25.00
Royal Bank of Canada Trims Russel Metals Target Price to C$25.00
Turquoise Hill Resources  Cut to “Speculative Buy” at TD Securities
Turquoise Hill Resources Cut to “Speculative Buy” at TD Securities
Western Forest Products  Stock Rating Lowered by Raymond James
Western Forest Products Stock Rating Lowered by Raymond James
Cedar Fair, L.P.  Expected to Earn Q2 2019 Earnings of $0.65 Per Share
Cedar Fair, L.P. Expected to Earn Q2 2019 Earnings of $0.65 Per Share
HELLA GMBH & CO KGAA  PT Set at €43.00 by Goldman Sachs Group
HELLA GMBH & CO KGAA PT Set at €43.00 by Goldman Sachs Group
Duerr  Given a €35.00 Price Target by Deutsche Bank Analysts
Duerr Given a €35.00 Price Target by Deutsche Bank Analysts


 
© 2006-2019 Zolmax.